A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Verona Pharma PLC stock. As of the latest transaction made, Maverick Capital LTD holds 4,215,973 shares of VRNA stock, worth $160 Million. This represents 2.52% of its overall portfolio holdings.

Number of Shares
4,215,973
Previous 3,092,807 36.32%
Holding current value
$160 Million
Previous $44.7 Million 171.22%
% of portfolio
2.52%
Previous 0.88%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.46 - $30.16 $17.4 Million - $33.9 Million
1,123,166 Added 36.32%
4,215,973 $121 Million
Q2 2024

Aug 14, 2024

BUY
$11.48 - $17.02 $15.1 Million - $22.4 Million
1,316,998 Added 74.16%
3,092,807 $44.7 Million
Q1 2024

May 15, 2024

BUY
$15.3 - $20.24 $1.83 Million - $2.41 Million
119,317 Added 7.2%
1,775,809 $28.6 Million
Q4 2023

Feb 14, 2024

BUY
$11.94 - $20.47 $19.8 Million - $33.9 Million
1,656,492 New
1,656,492 $32.9 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.31B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.